{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:52:39Z","timestamp":1791075159301,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/deed.de"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anaesthesiologie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00101-026-01732-9","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:16:07Z","timestamp":1790151367000},"page":"737-744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autoimmunenzephalitiden in der Intensivmedizin","Autoimmune encephalitis in intensive care medicine"],"prefix":"10.1007","volume":"75","author":[{"given":"Albrecht","family":"G\u00fcnther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Br\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"1732_CR1","doi-asserted-by":"publisher","unstructured":"Wandinger KP et al. (2018) Autoantibody-Mediated Encephalitis. Dtsch Arztebl Int 115(40):666-673. https:\/\/doi.org\/10.3238\/arztebl.2018.0666","DOI":"10.3238\/arztebl.2018.0666"},{"key":"1732_CR2","doi-asserted-by":"publisher","unstructured":"Dubey D et\u00a0al. (2018) Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 83(1):166-177. https:\/\/doi.org\/10.1002\/ana.25131","DOI":"10.1002\/ana.25131"},{"key":"1732_CR3","doi-asserted-by":"publisher","unstructured":"Br\u00e4mer D et\u00a0al. (2023) Autoimmune encephalitis \u2013 Challenges and management in intensive medical care. Nervenarzt 94(2):113-119. https:\/\/doi.org\/10.1007\/s00115-022-01423-x","DOI":"10.1007\/s00115-022-01423-x"},{"key":"1732_CR4","doi-asserted-by":"publisher","unstructured":"Sonneville R et al. (2019) Understanding auto-immune encephalitis in the ICU. Intensive Care Med 45(12):1795-1798. https:\/\/doi.org\/10.1007\/s00134-019-05773-0","DOI":"10.1007\/s00134-019-05773-0"},{"key":"1732_CR5","doi-asserted-by":"publisher","unstructured":"Hahn C et\u00a0al (2024) Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults. Can J Neurol Sci 5:1-21. https:\/\/doi.org\/10.1017\/cjn.2024.16","DOI":"10.1017\/cjn.2024.16"},{"key":"1732_CR6","doi-asserted-by":"publisher","unstructured":"Dalmau J et\u00a0al. (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091-8. https:\/\/doi.org\/10.1016\/S1474-4422(08)70224-2","DOI":"10.1016\/S1474-4422(08)70224-2"},{"key":"1732_CR7","doi-asserted-by":"publisher","unstructured":"Graus F, Dalmau J (2012) Paraneoplastic neurological syndromes. Curr Opin Neurol 25(6):795-801. https:\/\/doi.org\/10.1097\/WCO.0b013e328359da15","DOI":"10.1097\/WCO.0b013e328359da15"},{"key":"1732_CR8","doi-asserted-by":"publisher","unstructured":"Abboud H et\u00a0al. (2021) Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry 92(7):757-768. https:\/\/doi.org\/10.1136\/jnnp-2020-325300","DOI":"10.1136\/jnnp-2020-325300"},{"key":"1732_CR9","doi-asserted-by":"publisher","unstructured":"Dalmau J, Graus F (2018) Antibody-Mediated Encephalitis. N Engl J Med 378(9):840-851. https:\/\/doi.org\/10.1056\/NEJMra1708712","DOI":"10.1056\/NEJMra1708712"},{"key":"1732_CR10","doi-asserted-by":"publisher","unstructured":"Irani SR et\u00a0al. (2016) Voltage-gated potassium channel-complex autoimmunity and associated clinical syndromes. Handb Clin Neurol 133:185-97. https:\/\/doi.org\/10.1016\/B978-0-444-63432-0.00011-6","DOI":"10.1016\/B978-0-444-63432-0.00011-6"},{"key":"1732_CR11","doi-asserted-by":"publisher","first-page":"755875","DOI":"10.3389\/fncel.2021.755875","volume":"15","author":"K Bohmwald","year":"2021","unstructured":"Bohmwald K et\u00a0al. (2021) The Causes and Long-Term Consequences of Viral Encephalitis. Front Cell Neurosci 15:755875. https:\/\/doi.org\/10.3389\/fncel.2021.755875","journal-title":"Front Cell Neurosci"},{"key":"1732_CR12","doi-asserted-by":"publisher","unstructured":"Steiner I et\u00a0al. (2005) Viral encephalitis: a review of diagnostic methods and guidelines for management. Eur J Neurol 12(5):331-43. https:\/\/doi.org\/10.1111\/j.1468-1331.2005.01126.x","DOI":"10.1111\/j.1468-1331.2005.01126.x"},{"key":"1732_CR13","doi-asserted-by":"publisher","unstructured":"Solomon T et\u00a0al. (2012) Management of suspected viral encephalitis in adults \u2013 Association of British Neurologists and British Infection Association National Guidelines. J Infect 64(4):347-73. https:\/\/doi.org\/10.1016\/j.jinf.2011.11.014","DOI":"10.1016\/j.jinf.2011.11.014"},{"key":"1732_CR14","doi-asserted-by":"publisher","unstructured":"Graus F et\u00a0al. (2016) A\u00a0clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391-404. https:\/\/doi.org\/10.1016\/S1474-4422(15)00401-9","DOI":"10.1016\/S1474-4422(15)00401-9"},{"key":"1732_CR15","doi-asserted-by":"publisher","unstructured":"Granerod J et\u00a0al. (2010) Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 10(12):835-44. https:\/\/doi.org\/10.1016\/S1473-3099(10)70222-X","DOI":"10.1016\/S1473-3099(10)70222-X"},{"key":"1732_CR16","doi-asserted-by":"publisher","unstructured":"Mark DW et al. (2024) Oligoclonal bands. Pract Neurol 24(5):400-406. https:\/\/doi.org\/10.1136\/pn-2023-003814","DOI":"10.1136\/pn-2023-003814"},{"key":"1732_CR17","doi-asserted-by":"publisher","unstructured":"Farazmand et\u00a0al. (2011) Mollaret\u2019s meningitis and herpes simplex virus type\u00a02 infections. Int J STD AIDS 22(6):306-7. https:\/\/doi.org\/10.1258\/ijsa.2010.010405","DOI":"10.1258\/ijsa.2010.010405"},{"key":"1732_CR18","doi-asserted-by":"publisher","unstructured":"Gresa-Arribas N et\u00a0al. (2014) Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 13(2):167-77. https:\/\/doi.org\/10.1016\/S1474-4422(13)70282-5","DOI":"10.1016\/S1474-4422(13)70282-5"},{"key":"1732_CR19","doi-asserted-by":"publisher","unstructured":"Armangue T et\u00a0al. (2014) Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 75(2):317-23. https:\/\/doi.org\/10.1002\/ana.24083","DOI":"10.1002\/ana.24083"},{"key":"1732_CR20","doi-asserted-by":"crossref","unstructured":"Rosenow F et al. (2020) Status epilepticus im Erwachsenenalter, S2k-Leitlinie. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie.","DOI":"10.1007\/s00115-020-01036-2"},{"key":"1732_CR21","doi-asserted-by":"publisher","unstructured":"Schmitt SE et al. (2012) Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 79(11):1094-100. https:\/\/doi.org\/10.1212\/WNL.0b013e3182698cd8","DOI":"10.1212\/WNL.0b013e3182698cd8"},{"key":"1732_CR22","unstructured":"Geis C et\u00a0al. (2022) Autoimmune neurological disorders in intensive care medicine. Intensivmedizin up2date"},{"key":"1732_CR23","doi-asserted-by":"publisher","unstructured":"Venkatesan A et\u00a0al. (2023) Approach to acute encephalitis in the intensive care unit. Curr Opin Crit Care 29(2):89-98. https:\/\/doi.org\/10.1097\/MCC.0000000000001028","DOI":"10.1097\/MCC.0000000000001028"},{"key":"1732_CR24","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"HW Pfister","year":"2023","unstructured":"Pfister H-W et al. (2023) Ambulant erworbene bakterielle Meningoenzephalitis im Erwachsenenalter, S2k Leitlinie. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie"},{"key":"1732_CR25","doi-asserted-by":"publisher","unstructured":"Nosadini M et\u00a0al. (2015) Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother 15(12):1391-419. https:\/\/doi.org\/10.1586\/14737175.2015.1115720","DOI":"10.1586\/14737175.2015.1115720"},{"key":"1732_CR26","doi-asserted-by":"publisher","unstructured":"Titulaer MJ et\u00a0al. (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157-65. https:\/\/doi.org\/10.1016\/S1474-4422(12)70310-1","DOI":"10.1016\/S1474-4422(12)70310-1"},{"key":"1732_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-022-01411-1","author":"J Heine","year":"2023","unstructured":"Heine\u00a0J et\u00a0al. (2023) Autoimmune encephalitis-An update. Nervenarzt 94(6):525-537. https:\/\/doi.org\/10.1007\/s00115-022-01411-1","journal-title":"Nervenarzt"},{"key":"1732_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000514","volume":"6","author":"J Schubert","year":"2019","unstructured":"Schubert\u00a0J et\u00a0al. (2018) Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment. Neurol Neuroimmunol Neuroinflamm 6(1):e514. https:\/\/doi.org\/10.1212\/NXI.0000000000000514","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1732_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101562","volume":"62","author":"J Brenner","year":"2025","unstructured":"Brenner\u00a0J et\u00a0al. (2025) Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study. Lancet Reg Health Eur 62:101562. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101562","journal-title":"Lancet Reg Health Eur"},{"key":"1732_CR30","doi-asserted-by":"publisher","unstructured":"Wickel et al. (2020) Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis. Trials 21:625 https:\/\/doi.org\/10.1186\/s13063-020-04516-7","DOI":"10.1186\/s13063-020-04516-7"},{"key":"1732_CR31","doi-asserted-by":"crossref","unstructured":"Bien C & Holtkamp M (2017) \u201cAutoimmune Epilepsy\u201d: Encephalitis With Autoantibodies for Epileptologists. Epilepsy Currents 17(3):134-141.","DOI":"10.5698\/1535-7511.17.3.134"}],"container-title":["Die Anaesthesiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-026-01732-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00101-026-01732-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-026-01732-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:03:16Z","timestamp":1791072196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00101-026-01732-9"}},"subtitle":["Abgrenzung zu erregerbedingten Enzephalitiden","Differentiation from infectious encephalitis"],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1732"],"URL":"https:\/\/doi.org\/10.1007\/s00101-026-01732-9","relation":{},"ISSN":["2731-6858","2731-6866"],"issn-type":[{"value":"2731-6858","type":"print"},{"value":"2731-6866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0G\u00fcnther:\n                      A.\u00a0Finanzielle Interessen: Ipsen Pharma unrestricted grant f\u00fcr IIT. \u2013\u00a0Ipsen Pharma Vortragshonorare und Reisekosten f\u00fcr Kongress | Boehringer Ingelheim (Vortragshonorare) | Pfizer\/BMS (Vortragshonorare) | Shionogi (Vortragshonorar) | Merz (Vortragshonorare).\u00a0\u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00c4.: Ipsen Pharma Advisory Board. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Neurologe, Klinik f\u00fcr Neurologie, Universit\u00e4tsklinikum Jena; | 1.\u00a0Vorsitzender der DGNI Stiftung | Mitgliedschaften: DGN, DGNI, DEGUM, DIVI, IGNITE-Forschungsgruppe der DGNI.\n                      D.\u00a0Br\u00e4mer\n                      A.\u00a0Finanzielle Interessen: D.\u00a0Br\u00e4mer gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: OA, Uniklinikum Jena | Mitgliedschaften: DGN, DGNI, DSG.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}